{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:03:53Z","timestamp":1791475433262,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.msard.2021.103184","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T17:18:56Z","timestamp":1627838336000},"page":"103184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: A systematic review"],"prefix":"10.1016","volume":"55","author":[{"given":"Luiza Andraus","family":"Dantas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Steingraber","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda de Miranda","family":"Gauza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eduarda Bonetti","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Figueiredo da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eduarda Marchi","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Washigton Luiz Gomes de","family":"Medeiros Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Vin\u00edcius Magno","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103184_bib0001","article-title":"Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting","volume":"5","author":"Baldassari","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2021.103184_bib0002","article-title":"Prevalence of latent tuberculosis (TB) in the multiple sclerosis (MS) clinic and effect of MS treatment on TB testing","author":"Bouley","year":"2020","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2021.103184_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00430-016-0482-x","article-title":"Effect of teriflunomide on QuantiFERON-TB gold results","volume":"206","author":"Bua","year":"2017","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.msard.2021.103184_bib0004","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2018.1483330","article-title":"Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis","author":"Buonomo","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2021.103184_bib0005","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103184_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)61401-9","article-title":"Breathlessness, night sweats, and weight loss on natalizumab","author":"Dahdaleh","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103184_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci7070078","article-title":"Multiple sclerosis: immunopathology and treatment update","author":"Dargahi","year":"2017","journal-title":"Brain Sci."},{"key":"10.1016\/j.msard.2021.103184_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","author":"Epstein","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.msard.2021.103184_bib0009","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1586\/14737175.2014.962517","article-title":"How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?","volume":"14","author":"Fragoso","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.msard.2021.103184_bib0010","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103184_bib0011","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/acn3.491","article-title":"Infectious risk stratification in multiple sclerosis patients receiving immunotherapy","volume":"4","author":"Graf","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2021.103184_bib0012","doi-asserted-by":"crossref","unstructured":"Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberat\u00ee, A., Petticrew, M., Shekelle, P., Stewart, L.A., Group, P.P., 2015. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. 10.1186\/2046-4053-4-1.","DOI":"10.1136\/bmj.g7647"},{"key":"10.1016\/j.msard.2021.103184_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/1352458520952311","article-title":"The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement","author":"Moiola","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103184_bib0014","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jneuroim.2011.12.009","article-title":"Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab","volume":"243","author":"Mulero","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2021.103184_bib0015","article-title":"Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis","volume":"4","author":"Navas","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2021.103184_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101982","article-title":"Infections in patients diagnosed with multiple sclerosis: a multi-database study","volume":"41","author":"Persson","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103184_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/medicina56040202","article-title":"Active pulmonary tuberculosis triggered by interferon beta-1b therapy of multiple sclerosis: four case reports and a literature review","volume":"56","author":"Sirbu","year":"2020","journal-title":"Medicina"},{"key":"10.1016\/j.msard.2021.103184_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836913","article-title":"Pulsed immune reconstitution therapy in multiple sclerosis","author":"Sorensen","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103184_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103184_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/jim-2016-000339","article-title":"Update on disease-modifying therapies for multiple sclerosis","author":"Vargas","year":"2017","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.msard.2021.103184_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/CON.0000000000000245","article-title":"Central nervous system infections with immunomodulatory therapies","author":"Williamson","year":"2015","journal-title":"Contin. Lifelong Learn. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100451X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100451X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:38:34Z","timestamp":1786765114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482100451X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":21,"alternative-id":["S221103482100451X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103184","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103184"}}